ES3014985T3 - Diagnosis, prevention, and/or treatment of autoimmune diseases - Google Patents

Diagnosis, prevention, and/or treatment of autoimmune diseases Download PDF

Info

Publication number
ES3014985T3
ES3014985T3 ES17840379T ES17840379T ES3014985T3 ES 3014985 T3 ES3014985 T3 ES 3014985T3 ES 17840379 T ES17840379 T ES 17840379T ES 17840379 T ES17840379 T ES 17840379T ES 3014985 T3 ES3014985 T3 ES 3014985T3
Authority
ES
Spain
Prior art keywords
epitope
cells
pla2r
edc
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17840379T
Other languages
English (en)
Spanish (es)
Inventor
Quansheng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunowork LLC
Original Assignee
Immunowork LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunowork LLC filed Critical Immunowork LLC
Application granted granted Critical
Publication of ES3014985T3 publication Critical patent/ES3014985T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17840379T 2016-08-12 2017-08-11 Diagnosis, prevention, and/or treatment of autoimmune diseases Active ES3014985T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374382P 2016-08-12 2016-08-12
PCT/US2017/046626 WO2018031947A1 (en) 2016-08-12 2017-08-11 Diagnosis, prevention, and/or treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ES3014985T3 true ES3014985T3 (en) 2025-04-28

Family

ID=61163324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17840379T Active ES3014985T3 (en) 2016-08-12 2017-08-11 Diagnosis, prevention, and/or treatment of autoimmune diseases

Country Status (6)

Country Link
US (3) US11266717B2 (enExample)
EP (2) EP3497452B1 (enExample)
JP (2) JP7303107B2 (enExample)
CN (1) CN109891245B (enExample)
ES (1) ES3014985T3 (enExample)
WO (1) WO2018031947A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3497452B1 (en) * 2016-08-12 2025-03-05 Immunowork, LLC Diagnosis, prevention, and/or treatment of autoimmune diseases
EP3813885A4 (en) * 2018-05-02 2022-01-12 The Trustees of The University of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
EP3837547A4 (en) 2018-08-15 2022-03-02 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR IDENTIFICATION AND TREATMENT OF MEMBRANE NEPHROPATHY
EP4010704A1 (en) 2019-08-06 2022-06-15 Euroimmun Medizinische Labordiagnostika AG An improved autoantibody detection assay
WO2021055767A1 (en) 2019-09-19 2021-03-25 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating membranous nephropathy
US12590165B2 (en) 2020-03-06 2026-03-31 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating membranous nephropathy based on elevated Semaphorin 3B
CN112111015B (zh) * 2020-09-24 2021-12-07 苏州携创生物技术有限公司 PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用
CN112557670A (zh) * 2020-12-07 2021-03-26 东南大学 一种基于尿液外泌体pla2r检测imn的方法、试剂盒及其应用
BR102021022687A2 (pt) 2020-12-11 2022-06-28 Euroimmun Medizinische Labordiagnostika Ag Método e reagentes para diagnosticar nefropatia membranosa
EP4380963A4 (en) * 2021-08-05 2025-06-04 The Trustees of The University of Pennsylvania Compositions and methods of chimeric autoantibody receptor cells expressing extended phospholipase a2 receptor fragments
CN114588881B (zh) * 2022-03-07 2023-07-18 大连理工大学 免疫吸附剂及其制备方法
US20250230261A1 (en) * 2022-03-23 2025-07-17 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
CN116082517B (zh) * 2022-05-26 2025-08-22 成都地奥制药集团有限公司 融合蛋白及其用途
WO2024147113A1 (en) * 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
CN115951047A (zh) * 2023-02-10 2023-04-11 大连大学 自身免疫性水疱病PBMCs直接免疫荧光诊断试剂盒
CN121443630A (zh) * 2023-05-08 2026-01-30 卡努佩免疫治疗公司 用于治疗膜性肾病的ig样融合蛋白
US20250382348A1 (en) * 2024-06-13 2025-12-18 Astero BioPharma LLC Approaches for the selective depletion of pla2r-specific antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2051989T3 (es) 1988-10-21 1994-07-01 Akzo Nv Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune.
JPH07278196A (ja) * 1994-04-05 1995-10-24 Shionogi & Co Ltd ヒトｉ型ホスホリパーゼａ２レセプター
JP2004505029A (ja) 2000-08-01 2004-02-19 ザ・ユニバーシティ・オブ・カンザス 細胞内に取り込まれるペプチド−薬剤複合体
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8491840B2 (en) * 2008-07-14 2013-07-23 Samsung Electronics Co., Ltd. Microfluidic device, sample analyzing method using the same, and dilution ratio measuring method
ES2535640T3 (es) * 2008-07-18 2015-05-13 Boston Medical Center Corporation Diagnósticos para nefropatía membranosa
US9156854B2 (en) 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
FI3467509T3 (fi) * 2011-05-04 2026-02-11 Cellular Tech Ltd Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
WO2015004603A1 (en) * 2013-07-09 2015-01-15 Institut National De La Sante Et De La Recherche Medicale Anti-pla2r antibody and uses thereof
GB201410108D0 (en) 2014-06-06 2014-07-23 Univ Manchester Peptides, and methods and apparatus utilising same
CN104849452A (zh) * 2015-05-14 2015-08-19 深圳市伯劳特生物制品有限公司 一种pla2r抗体定量检测试纸条及制作、检测方法
CN105510575A (zh) 2015-12-04 2016-04-20 深圳市伯劳特生物制品有限公司 抗磷脂酶A2受体抗体IgG试剂盒及检测方法
EP3497452B1 (en) * 2016-08-12 2025-03-05 Immunowork, LLC Diagnosis, prevention, and/or treatment of autoimmune diseases

Also Published As

Publication number Publication date
JP7411718B2 (ja) 2024-01-11
EP4644899A3 (en) 2026-04-08
EP3497452B1 (en) 2025-03-05
CN109891245A (zh) 2019-06-14
JP7303107B2 (ja) 2023-07-04
EP3497452C0 (en) 2025-03-05
US11266717B2 (en) 2022-03-08
US20220193188A1 (en) 2022-06-23
US20240252590A1 (en) 2024-08-01
EP3497452A4 (en) 2020-01-22
JP2019524884A (ja) 2019-09-05
EP3497452A1 (en) 2019-06-19
CN109891245B (zh) 2023-05-05
EP4644899A2 (en) 2025-11-05
US20190183969A1 (en) 2019-06-20
JP2022097596A (ja) 2022-06-30
WO2018031947A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
US20240252590A1 (en) Method of identifying and treating membranous nephropathy
US20260000773A1 (en) Bicyclic peptide ligands specific for epha2
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
US20230151068A1 (en) Peptide compositions and methods of use thereof for disrupting tead interactions
KR102581747B1 (ko) 표적 세포 표면 편집을 위한 접합체
ES2788151T3 (es) Kits y ensayos de diagnóstico para la detección del receptor 1 de folato
ES2932777T3 (es) Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos
US11013814B2 (en) Cartilage-homing peptide conjugates and methods of use thereof
JP2020532509A (ja) 活性化可能抗ｃｄ１６６抗体およびその使用方法
ES2619681T3 (es) Novedosos epítopos P2X7
EP1297002A2 (en) Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
US20220024983A1 (en) Bicyclic peptide ligands specific for il-17
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
ES2886642T3 (es) Factor antisecretor 17
US20210171589A1 (en) Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
US20240285785A1 (en) Targeting sortilin
WO2021026376A1 (en) Composition and use of humoral immune suppressor antagonists for the treatment of humoral immuno-suppressed diseases
US20210252159A1 (en) Conjugates of cartilage-homing peptides
WO2025083185A1 (en) Reducing off-target accumulation of targeted pharmaceutical compounds
CN121038818A (zh) 用于治疗癌症的b7-h4治疗性结合分子
US20230033370A1 (en) Bicyclic peptide ligands specific for il-17
WO2021123770A1 (en) Bicyclic peptide ligands specific for il-17
US20230039677A1 (en) Bicyclic peptide ligands specific for il-17